Elektrofi website screenshot

Elektrofi

Elektrofi is a Boston-based biopharmaceutical formulation technology company reinventing how biologic therapies are delivered to patients. Its Hypercon ultra-high-concentration microparticle platform and Elektroject process turn monoclonal antibodies, therapeutic proteins, and other large-molecule drugs into stable, syringe-injectable formulations suited to small-volume, at-home subcutaneous self-administration instead of intravenous infusion. The company has partnered with Eli Lilly and Janssen Biotech (Johnson & Johnson) on multi-target drug-delivery collaborations, and was acquired by Halozyme Therapeutics in November 2025. Elektrofi is a biotechnology company and does not publish a public developer API; this API Evangelist profile tracks it as a company entity within the network.

Elektrofi is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Drug Delivery, and Biologics.

Elektrofi’s developer surface includes engineering blog and 4 more developer resources.

🌐 Visit website 📡 Source on GitHub
3.8/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0
0 APIs
CompanyBiotechnologyPharmaceuticalsDrug DeliveryBiologicsFormulation TechnologySubcutaneousLife Sciences

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0
Composite quality — 3.8/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 0.4 / 17
Access Clarity 0.0 / 17
Operational Transparency 0.0 / 11
Contract Governance 0.0 / 10
Discoverability 4.3 / 9
Regulatory Posture 1.1 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
Documented Reversibility 0 / 6
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/elektrofi: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Elektrofi Domain Security

TLSv1.3 · HSTS · DMARC

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Company 3

The organization behind the API

Website
Website
 About
About
 Blog
Blog

Other 1

Properties that don't map to a standard resource type

Team
Team

Source (apis.yml)

apis.yml Raw ↑ 
aid: elektrofi
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/elektrofi.png
name: Elektrofi
description: Elektrofi is a Boston-based biopharmaceutical formulation technology company reinventing how biologic therapies
  are delivered to patients. Its Hypercon ultra-high-concentration microparticle platform and Elektroject process turn monoclonal
  antibodies, therapeutic proteins, and other large-molecule drugs into stable, syringe-injectable formulations suited to
  small-volume, at-home subcutaneous self-administration instead of intravenous infusion. The company has partnered with Eli
  Lilly and Janssen Biotech (Johnson & Johnson) on multi-target drug-delivery collaborations, and was acquired by Halozyme
  Therapeutics in November 2025. Elektrofi is a biotechnology company and does not publish a public developer API; this API
  Evangelist profile tracks it as a company entity within the network.
url: https://raw.githubusercontent.com/api-evangelist/elektrofi/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- general-catalyst
x-tier: stub
x-tier-reason: portfolio-lead
x-acquired-by: halozyme
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Drug Delivery
- Biologics
- Formulation Technology
- Subcutaneous
- Life Sciences
apis: []
common:
- type: DomainSecurity
  url: security/elektrofi-domain-security.yml
- type: Website
  url: https://www.elektrofi.com/
- type: About
  url: https://www.elektrofi.com/about
- type: Blog
  url: https://www.elektrofi.com/news
- type: Team
  url: https://www.elektrofi.com/team
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence